Venn and Uni­ver­si­ty of Utah part­ner on im­muno-on­col­o­gy mol­e­cule; Bio­gen los­ing an­oth­er ex­ec

→  Venn Ther­a­peu­tics plans to ad­vance a small mol­e­cule de­signed by Haitao (Mark) Ji at the Uni­ver­si­ty of Utah. The mol­e­cule is a β-catenin/BCL9 in­hibitor that they be­lieve will make tu­mors more sus­cep­ti­ble to the body’s im­mune re­sponse. β-catenin sig­nal­ing is un­der­stood to be re­spon­si­ble for can­cel cells evad­ing an­ti-tu­mor im­mu­ni­ty. Since de­vel­op­ing the mol­e­cule, Ji has moved to the Uni­ver­si­ty of South Flori­da‘s Tam­pa Bay Tech­nol­o­gy In­cu­ba­tor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER